Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A strong showing for SM07883
September 2019
SHARING OPTIONS:

SAN DIEGO—In recent news from Samumed LLC, the company reported on the publication of preclinical data on SM07883 in Alzheimer’s disease that shows that the candidate inhibits tau pathology and associated neuroinflammation. The article appeared in Aging Cell. Among other results, SM07883 was found to have good oral bioavailability and brain distribution across several species and was well tolerated, with significant improvements in general health, weight gain and functional improvement during motor tasks. SM07883 demonstrated potent, specific inhibition of DYRK1A and GSK-3b, kinases thought to contribute to tau pathology and β-amyloid production, and led to reduced tau phosphorylation in vitro and in vivo. Additionally, mice treated with the compound presented with a significant reduction in disease-associated neuroinflammation compared to vehicle.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.